One-Stone-Two-Birds Carrier-Free Nano-Cocktail Enables Synergistic Eradication of Cancer Cells/Stem Cells in Breast Cancer Treatment

Abstract

Cancer stem cells (CSCs) are widely recognized as the culprits of chemoresistance, tumor metastasis, and relapse. Moreover, most chemotherapeutic drugs not only fail to eliminate CSCs effectively, but also induce the acquisition of stemness characteristics in non-stem cancer cells. Herein, we propose a cancer cells/CSCs double-killing modality for breast cancer treatment. Specifically, a carrier-free nano-cocktail is developed through the precise co-assembly of a redox-responsive docetaxel (DTX) dimeric prodrug and salinomycin (SAL, an anti-CSCs drug). Precision combination of DTX and SAL not only shows synergistic tumor-killing activity, but also sharply reduces the proportion of CSCs in tumors. More importantly, tumor-specific prodrug activation-initiated drug release from the nano-cocktail confers high drug co-delivery efficiency and low off-target toxicity risk. As expected, such a one-stone-two-birds nanomedicine presents satisfactory performance on tumor stemness eradication, antitumor responses, and safety in both xenograft and orthotopic 4T1 breast cancer mouse models. This study advances cancer cells/CSCs double-killing nanotherapeutics towards clinical breast cancer therapy.

Keywords

cancer stem cells / docetaxel prodrug / nano-cocktail / salinomycin / synergistic chemotherapy

References

[1] R. L. Siegel, K. D. Miller, N. S. Wagle, and A. Jemal, “Cancer Statistics, 2023,” CA: A Cancer Journal for Clinicians 73 (2023): 17.

[2] Y. Song, Y. Du, C. Hu, et al., “Metformin-Mediated Immunosuppressive Microenvironment Remodeling in Combination with Chemotherapy via a Spatial-Specific Multi-Responsive Carrier-Free Self-Assembled Nanoparticle,” Advanced Functional Materials 34 (2024): 202316145.

[3] S. Theivendran, S. Lazarev, and C. Yu, “Mesoporous Silica/Organosilica Nanoparticles for Cancer Immunotherapy,” Exploration (Beijing, China) 3 (2023): 20220086.

[4] Z. Fu, S. Li, S. Han, C. Shi, and Y. Zhang, “Antibody Drug Conjugate: The “Biological Missile” for Targeted Cancer Therapy,” Signal Transduction and Targeted Therapy 7 (2022): 93, https://doi.org/10.1038/s41392-022-00947-7.

[5] U. Anand, A. Dey, A. K. S. Chandel, et al., “Cancer Chemotherapy and Beyond: Current Status, Drug Candidates, Associated Risks and Progress in Targeted Therapeutics,” Genes & Diseases 10 (2023): 1367–1401, https://doi.org/10.1016/j.gendis.2022.02.007.

[6] R. Lin, J. Yan, B. Gong, et al., “Self-Delivered Transformable Nanosystem Capable of Enhancing Photodynamic Effectiveness and Multi-Target Ameliorating Immunosuppression for Treatment of Breast Cancer and Lung Metastasis,” Advanced Functional Materials 34, no. 42 (2024): 2405051.

[7] F. Zhou, L. Huang, S. Li, et al., “From Structural Design to Delivery: mRNA Therapeutics for Cancer Immunotherapy,” Exploration (Beijing, China) 4 (2024): 20210146.

[8] F. Yang, S. Li, Q. Ji, et al., “Highly Efficient Printed Quantum Dot Light-Emitting Diodes Through Ultrahigh-Definition Double-Layer Transfer Printing,” Advanced Science 11 (2024): 2309786.

[9] T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman, “Stem Cells, Cancer, and Cancer Stem Cells,” Nature 414 (2001): 105–111, https://doi.org/10.1038/35102167.

[10] C. T. Jordan, M. L. Guzman, and M. Noble, “Cancer Stem Cells,” New England Journal of Medicine 355 (2006): 1253–1261, https://doi.org/10.1056/NEJMra061808.

[11] T. Lapidot, C. Sirard, J. Vormoor, et al., “A Cell Initiating Human Acute Myeloid Leukaemia After Transplantation Into SCID Mice,” Nature 367 (1994): 645–648, https://doi.org/10.1038/367645a0.

[12] J. P. Medema, “Cancer Stem Cells: The Challenges Ahead,” Nature Cell Biology 15 (2013): 338–344, https://doi.org/10.1038/ncb2717.

[13] T. Chiba, A. Kamiya, O. Yokosuka, and A. Iwama, “Cancer Stem Cells in Hepatocellular Carcinoma: Recent Progress and Perspective,” Cancer Letters 286 (2009): 145–153, https://doi.org/10.1016/j.canlet.2009.04.027.

[14] J. D. Lathia, S. C. Mack, E. E. Mulkearns-Hubert, C. L. Valentim, and J. N. Rich, “Cancer Stem Cells in Glioblastoma,” Genes & Development 29 (2015): 1203–1217, https://doi.org/10.1101/gad.261982.115.

[15] Z. Mirza and S. Karim, “Nanoparticles-Based Drug Delivery and Gene Therapy for Breast Cancer: Recent Advancements and Future Challenges,” Seminars in Cancer Biology 69 (2021): 226–237.

[16] G. Bianchini, J. M. Balko, I. A. Mayer, M. E. Sanders, and L. Gianni, “Triple-Negative Breast Cancer: Challenges and Opportunities of a Heterogeneous Disease,” Nature Reviews Clinical Oncology 13 (2016): 674–690, https://doi.org/10.1038/nrclinonc.2016.66.

[17] X. Bai, J. Ni, J. Beretov, P. Graham, and Y. Li, “Cancer Stem Cell in Breast Cancer Therapeutic Resistance,” Cancer Treatment Reviews 69 (2018): 152–163, https://doi.org/10.1016/j.ctrv.2018.07.004.

[18] J. Guan, Y. Wu, X. Liu, et al., “A Novel Prodrug and Its Nanoformulation Suppress Cancer Stem Cells by Inducing Immunogenic Cell Death and Inhibiting Indoleamine 2, 3-dioxygenase,” Biomaterials 279 (2021): 121180, https://doi.org/10.1016/j.biomaterials.2021.121180.

[19] T. Shibue and R. A. Weinberg, “EMT, CSCs, and Drug Resistance: The Mechanistic Link and Clinical Implications,” Nature Reviews Clinical Oncology 14 (2017): 611–629, https://doi.org/10.1038/nrclinonc.2017.44.

[20] X. Jiang, J. Liu, J. Mao, et al., “Pharmacological Ascorbate Potentiates Combination Nanomedicines and Reduces Cancer Cell Stemness to Prevent Post-Surgery Recurrence and Systemic Metastasis,” Biomaterials 295 (2023): 122037, https://doi.org/10.1016/j.biomaterials.2023.122037.

[21] L. Yang, P. Shi, G. Zhao, et al., “Targeting Cancer Stem Cell Pathways for Cancer Therapy,” Signal Transduction and Targeted Therapy 5 (2020): 8, https://doi.org/10.1038/s41392-020-0110-5.

[22] W.-D. Wang, Y.-Y. Guo, Z.-L. Yang, G.-L. Su, and Z.-J. Sun, “Sniping Cancer Stem Cells with Nanomaterials,” ACS Nano 17 (2023): 23262–23298.

[23] S. Shen, J.-X. Xia, and J. Wang, “Nanomedicine-Mediated Cancer Stem Cell Therapy,” Biomaterials 74 (2016): 1–18, https://doi.org/10.1016/j.biomaterials.2015.09.037.

[24] S. Shen, X. Xu, S. Lin, et al., “A Nanotherapeutic Strategy to Overcome Chemotherapeutic Resistance of Cancer Stem-Like Cells,” Nature Nanotechnology 16 (2021): 104–113, https://doi.org/10.1038/s41565-020-00793-0.

[25] P. B. Gupta, T. T. Onder, G. Jiang, et al., “Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening,” Cell 138 (2009): 645–659, https://doi.org/10.1016/j.cell.2009.06.034.

[26] D. Qi, Y. Liu, J. Li, J. H. Huang, X. Hu, and E. Wu, “Salinomycin as a Potent Anticancer Stem Cell Agent: State of the Art and Future Directions,” Medicinal Research Reviews 42 (2022): 1037–1063, https://doi.org/10.1002/med.21870.

[27] X. Huang, B. Borgström, J. Stegmayr, et al., “The Molecular Basis for Inhibition of Stemlike Cancer Cells by Salinomycin,” ACS Central Science 4 (2018): 760–767, https://doi.org/10.1021/acscentsci.8b00257.

[28] Y. Chen, T. Zhao, M. Bai, et al., “Emerging Small Molecule-Engineered Hybrid Nanomedicines for Cancer Therapy,” Chemical Engineering Journal 435 (2022): 135160, https://doi.org/10.1016/j.cej.2022.135160.

[29] X. Sun, S. Zhang, P. Wang, et al., “A Molecularly Tailored Closed-Loop Tumor Cell Energy Nanodepleter for Cancer Starvation Therapy,” Nano Today 57 (2024): 102374, https://doi.org/10.1016/j.nantod.2024.102374.

[30] Y. Cui, M. Zhao, Y. Yang, et al., “Reversal of Epithelial-Mesenchymal Transition and Inhibition of Tumor Stemness of Breast Cancer Cells Through Advanced Combined Chemotherapy,” Acta Biomaterialia 152 (2022): 380–392, https://doi.org/10.1016/j.actbio.2022.08.024.

[31] Z. Zhang, Q. Deng, C. Xiao, Z. Li, and X. Yang, “Rational Design of Nanotherapeutics Based on the Five Features Principle for Potent Elimination of Cancer Stem Cells,” Accounts of Chemical Research 55 (2022): 526–536, https://doi.org/10.1021/acs.accounts.1c00635.

[32] Z. Wang, S. Zhang, Z. Kong, et al., “Self-Adaptive Nanoassembly Enabling Turn-on Hypoxia Illumination and Periphery/Center Closed-Loop Tumor Eradication,” Cell Reports Medicine 4 (2023): 101014, https://doi.org/10.1016/j.xcrm.2023.101014.

[33] H. Zhang, J. Wang, H. Wu, et al., “On-Site Self-Penetrating Nanomedicine Enabling Dual-Priming Drug Activation and Inside-Out Thrombus Ablation,” ACS Nano 18 (2024): 34683–34697, https://doi.org/10.1021/acsnano.4c09986.

[34] H. Zhang, S. Zhang, S. Liu, et al., “Self-Actuated Clot-Piercing Nanoassembly Enabling Adaptable Drug Activation and Synergistic Thrombus Ablation,” Advanced Functional Materials 2025, no. 35 (2025): 2416968, https://doi.org/10.1002/adfm.202416968.

[35] Y. Wang, P. Wang, W. Li, et al., “Cascaded Multiresponsive Supramolecular Dimer-Engineered Nano-Modulator Enabling Spatiotemporally Adaptable Tumor Immune Microenvironment Remodeling in Photodynamic Immunotherapy,” Nano Today 56 (2024): 102305, https://doi.org/10.1016/j.nantod.2024.102305.

[36] H. Zhang, J. Wang, R. Han, B. Sun, and C. Luo, “Bioorthogonal Chemistry-Driven Anticancer Nanotherapeutics,” Trends in Chemistry 5 (2023): 697–710, https://doi.org/10.1016/j.trechm.2023.05.006.

[37] Z. Lin, Y. Wang, W. Li, et al., “A Natural Compound-Empowered Podophyllotoxin Prodrug Nanoassembly Magnifies Efficacy-Toxicity Benefits in Cancer Chemotherapy,” Asian Journal of Pharmaceutical Sciences 19 (2024): 100892, https://doi.org/10.1016/j.ajps.2024.100892.

[38] S. Zhang, J. Guan, M. Sun, et al., “Self-Delivering Prodrug-Nanoassemblies Fabricated by Disulfide Bond Bridged Oleate Prodrug of Docetaxel for Breast Cancer Therapy,” Drug Delivery 24 (2017): 1460–1469, https://doi.org/10.1080/10717544.2017.1381201.

[39] X. Zhang, N. Li, S. Zhang, et al., “Emerging Carrier-Free Nanosystems Based on Molecular Self-Assembly of Pure Drugs for Cancer Therapy,” Medicinal Research Reviews 40 (2020): 1754–1775, https://doi.org/10.1002/med.21669.

[40] S. Li, X. Shan, Y. Wang, et al., “Dimeric Prodrug-Based Nanomedicines for Cancer Therapy,” Journal of Controlled Release 326 (2020): 510–522, https://doi.org/10.1016/j.jconrel.2020.07.036.

[41] C. Wang, S. Li, B. Qian, et al., “AIEgen-Functionalized Nanoprobes and Nanomedicines for Cancer Diagnosis and Therapy,” Coordination Chemistry Reviews 520 (2024): 216148, https://doi.org/10.1016/j.ccr.2024.216148.

[42] F. Yang, Q. Ji, R. Liao, et al., “Precisely Engineering a Dual-Drug Cooperative Nanoassembly for Proteasome Inhibition-Potentiated Photodynamic Therapy,” Chinese Chemical Letters 33 (2022): 1927–1932, https://doi.org/10.1016/j.cclet.2021.11.056.

[43] R. Liu, C. Luo, Z. Pang, et al., “Advances of Nanoparticles as Drug Delivery Systems for Disease Diagnosis and Treatment,” Chinese Chemical Letters 34 (2023): 107518, https://doi.org/10.1016/j.cclet.2022.05.032.

[44] H. Zhang, Z. Zhao, S. Sun, et al., “Molecularly Self-Fueled Nano-Penetrator for Nonpharmaceutical Treatment of Thrombosis and Ischemic Stroke,” Nature Communications 14 (2023): 255, https://doi.org/10.1038/s41467-023-35895-5.

[45] B. Sun, C. Luo, H. Yu, et al., “Disulfide Bond-Driven Oxidation- and Reduction-Responsive Prodrug Nanoassemblies for Cancer Therapy,” Nano Letters 18 (2018): 3643–3650, https://doi.org/10.1021/acs.nanolett.8b00737.

[46] C. Luo, J. Sun, D. Liu, et al., “Self-Assembled Redox Dual-Responsive Prodrug-Nanosystem Formed by Single Thioether-Bridged Paclitaxel-Fatty Acid Conjugate for Cancer Chemotherapy,” Nano Letters 16 (2016): 5401–5408, https://doi.org/10.1021/acs.nanolett.6b01632.

[47] Y. Wang, C. Luo, S. Zhou, et al., “Investigating the Crucial Roles of Aliphatic Tails in Disulfide Bond-Linked Docetaxel Prodrug Nanoassemblies,” Asian Journal of Pharmaceutical Sciences 16 (2021): 643–652, https://doi.org/10.1016/j.ajps.2021.02.001.

[48] S. Zuo, B. Sun, Y. Yang, et al., “Probing the Superiority of Diselenium Bond on Docetaxel Dimeric Prodrug Nanoassemblies: Small Roles Taking Big Responsibilities,” Small 16 (2020): 2005039, https://doi.org/10.1002/smll.202005039.

[49] J. J. Rennick, A. P. Johnston, and R. G. Parton, “Key Principles and Methods for Studying the Endocytosis of Biological and Nanoparticle Therapeutics,” Nature Nanotechnology 16 (2021): 266–276, https://doi.org/10.1038/s41565-021-00858-8.

[50] H.-M. Zhou, J.-G. Zhang, X. Zhang, and Q. Li, “Targeting Cancer Stem Cells for Reversing Therapy Resistance: Mechanism, Signaling, and Prospective Agents,” Signal Transduction and Targeted Therapy 6 (2021): 62, https://doi.org/10.1038/s41392-020-00430-1.

RIGHTS & PERMISSIONS

2025 The Author(s). Exploration published by Henan University and John Wiley & Sons Australia, Ltd.